BioCentury | Oct 25, 2018
Distillery Therapeutics

Neurology

...Ltd. have JTT-851, an oral FFAR1 agonist, in Phase II testing for Type II diabetes. Connexios Life Sciences Pvt. Ltd....
BioCentury | Feb 2, 2017
Distillery Therapeutics

Endocrine / Metabolic

...P11187 , an orally active FFAR1 agonist, in Phase I testing for Type II diabetes. Connexios Life Sciences Pvt. Ltd....
BioCentury | Feb 21, 2013
Distillery Therapeutics

Indication: Musculoskeletal disease

...Pharmaceutical Co. Ltd.'s TAK-875, a GPR40 agonist, is in Phase III testing to treat diabetes. Connexios Life Sciences Pvt. Ltd....
BioCentury | Jan 31, 2013
Distillery Therapeutics

Indication: Endocrine/metabolic disease

...diabetes drug Glactiv sitagliptin. Next steps include testing the compounds in rodent models of diabetes. Connexios Life Sciences Pvt. Ltd....
BioCentury | Aug 9, 2012
Distillery Therapeutics

Indication: Endocrine/metabolic disease

...Takeda Pharmaceutical Co. Ltd. has TAK-875 in Phase III testing to treat type 2 diabetes. Connexios Life Sciences Pvt. Ltd....
BioCentury | Feb 16, 2012
Targets & Mechanisms

Still un-sirtuin

...Ltd. , which is marketed in Japan to treat asthma and stroke. Betagenon AB and Connexios Life Sciences Pvt. Ltd....
BioCentury | Aug 22, 2011
Product Development

Beta testing GPR40

...and therefore warrant use in the earliest stages of disease. Takeda Pharmaceutical Co. Ltd. and Connexios Life Sciences Pvt. Ltd....
...reduction that looks to be competitive with any other diabetes drug. In vitro data from Connexios...
...rising glucose by delivering an acute, rapid rise of insulin known as the first phase. Connexios...
BioCentury | Jul 4, 2011
Clinical News

Connexios preclinical data

...vs. vehicle-treated controls. Data were presented at the American Diabetes Association meeting in San Diego. Connexios Life Sciences Pvt. Ltd....
BioCentury | Apr 12, 2010
Strategy

Stahel sees Scale in India

...Indian biotech Connexios Life Sciences Pvt. Ltd. is hoping to pattern itself after Western R&D-focused biotechs by building a pipeline...
...and marketing acumen to the science that is already in development. Like other small biotechs, Connexios...
...drug delivery company Cosmo Pharmaceuticals S.p.A. and cancer and neurology company EUSA Pharma Inc. Connexios...
BioCentury | Mar 8, 2010
Company News

Connexios board of directors update

Connexios Life Sciences Pvt. Ltd. , Bangalore, India Business: Endocrine, Metabolic Appointed: Rolf Stahel as chairman, formerly CEO of Shire plc WIR Staff...
Items per page:
1 - 10 of 11
BioCentury | Oct 25, 2018
Distillery Therapeutics

Neurology

...Ltd. have JTT-851, an oral FFAR1 agonist, in Phase II testing for Type II diabetes. Connexios Life Sciences Pvt. Ltd....
BioCentury | Feb 2, 2017
Distillery Therapeutics

Endocrine / Metabolic

...P11187 , an orally active FFAR1 agonist, in Phase I testing for Type II diabetes. Connexios Life Sciences Pvt. Ltd....
BioCentury | Feb 21, 2013
Distillery Therapeutics

Indication: Musculoskeletal disease

...Pharmaceutical Co. Ltd.'s TAK-875, a GPR40 agonist, is in Phase III testing to treat diabetes. Connexios Life Sciences Pvt. Ltd....
BioCentury | Jan 31, 2013
Distillery Therapeutics

Indication: Endocrine/metabolic disease

...diabetes drug Glactiv sitagliptin. Next steps include testing the compounds in rodent models of diabetes. Connexios Life Sciences Pvt. Ltd....
BioCentury | Aug 9, 2012
Distillery Therapeutics

Indication: Endocrine/metabolic disease

...Takeda Pharmaceutical Co. Ltd. has TAK-875 in Phase III testing to treat type 2 diabetes. Connexios Life Sciences Pvt. Ltd....
BioCentury | Feb 16, 2012
Targets & Mechanisms

Still un-sirtuin

...Ltd. , which is marketed in Japan to treat asthma and stroke. Betagenon AB and Connexios Life Sciences Pvt. Ltd....
BioCentury | Aug 22, 2011
Product Development

Beta testing GPR40

...and therefore warrant use in the earliest stages of disease. Takeda Pharmaceutical Co. Ltd. and Connexios Life Sciences Pvt. Ltd....
...reduction that looks to be competitive with any other diabetes drug. In vitro data from Connexios...
...rising glucose by delivering an acute, rapid rise of insulin known as the first phase. Connexios...
BioCentury | Jul 4, 2011
Clinical News

Connexios preclinical data

...vs. vehicle-treated controls. Data were presented at the American Diabetes Association meeting in San Diego. Connexios Life Sciences Pvt. Ltd....
BioCentury | Apr 12, 2010
Strategy

Stahel sees Scale in India

...Indian biotech Connexios Life Sciences Pvt. Ltd. is hoping to pattern itself after Western R&D-focused biotechs by building a pipeline...
...and marketing acumen to the science that is already in development. Like other small biotechs, Connexios...
...drug delivery company Cosmo Pharmaceuticals S.p.A. and cancer and neurology company EUSA Pharma Inc. Connexios...
BioCentury | Mar 8, 2010
Company News

Connexios board of directors update

Connexios Life Sciences Pvt. Ltd. , Bangalore, India Business: Endocrine, Metabolic Appointed: Rolf Stahel as chairman, formerly CEO of Shire plc WIR Staff...
Items per page:
1 - 10 of 11